IL6 and pulmonary fibrosis: Oroxylin A reduced inflammatory score and bronchiolar epithelium thickness, inhibited airway construction and central airway resistance, improved pulmonary fibrosis, increased inspiratory capacity and quasi‐static compliance, and suppressed IL‐1β and IL‐6 activity levels in mice model of RP (Figure 3).